Of all stroke patients, currently between 1–8% [3]–[5] are treated with tPA worldwide and around 11% (ranging from 4–26%) within the Netherlands [6], while 24–31% may be achieved in optimized settings [7], [8]. The gene discussed is PLAT; the disease is stroke disorder.